Search

Your search keyword '"Vancheri Carlo"' showing total 560 results
Start Over Author "Vancheri Carlo" Language english
560 results on '"Vancheri Carlo"'

2. Clinical characteristics, use and switch of drugs for obstructive airway diseases among patients with COPD experiencing an exacerbation: a retrospective analysis of Italian administrative healthcare data

Author

Dondi, Letizia, Ronconi, Giulia, Calabria, Silvia, Dell’Anno, Irene, Dondi, Leonardo, Piccinni, Carlo, Brignoli, Ovidio, Canonica, Giorgio Walter, Carone, Mauro, Di Marco, Fabiano, Micheletto, Claudio, Vancheri, Carlo, Pedrini, Antonella, Addesi, Alice, Esposito, Immacolata, and Martini, Nello

Published
2024
Full Text
View/download PDF

4. Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury

Author

Crimi Nunzio, Sortino Mariangela, Muià Carmelo, Gili Elisa, Mazzon Emanuela, Genovese Tiziana, Failla Marco, Caputi Achille P, Cuzzocrea Salvatore, and Vancheri Carlo

Subjects
Diseases of the respiratory system, RC705-779
Abstract

Abstract Leukotrienes are increased locally in idiopathic pulmonary fibrosis. Furthermore, a role for these arachidonic acid metabolites has been thoroughly characterized in the animal bleomycin model of lung fibrosis by using different gene knock-out settings. We investigated the efficacy of pharmacological inhibition of leukotrienes activity in the development of bleomycin-induced lung injury by comparing the responses in wild-type mice with mice treated with zileuton, a 5-lipoxygenase inhibitor and MK-571, a cys-leukotrienes receptor antagonist. Mice were subjected to intra-tracheal administration of bleomycin or saline and were assigned to receive either MK-571 at 1 mg/Kg or zileuton at 50 mg/Kg daily. One week after bleomycin administration, BAL cell counts, lung histology with van Gieson for collagen staining and immunohistochemical analysis for myeloperoxidase, IL-1 and TNF-α were performed. Following bleomycin administration both MK-571 and zileuton treated mice exhibited a reduced degree of lung damage and inflammation when compared to WT mice as shown by the reduction of:(i) loss of body weight, (ii) mortality rate, (iii) lung infiltration by neutrophils (myeloperoxidase activity, BAL total and differential cell counts), (iv) lung edema, (v) histological evidence of lung injury and collagen deposition, (vi) lung myeloperoxidase, IL-1 and TNF-α staining. This is the first study showing that the pharmacological inhibition of leukotrienes activity attenuates bleomycin-induced lung injury in mice. Given our results as well as those coming from genetic studies, it might be considered meaningful to trial this drug class in the treatment of pulmonary fibrosis, a disease that still represents a major challenge to medical treatment.

Published
2006
Full Text
View/download PDF

5. Altered intercellular communication in lung fibroblast cultures from patients with idiopathic pulmonary fibrosis

Author

Crimi Nunzio, Gili Elisa, Tomaselli Valerio, Mastruzzo Claudio, Failla Marco, Trovato-Salinaro Elisa, Trovato-Salinaro Angela, Condorelli Daniele, and Vancheri Carlo

Subjects
Diseases of the respiratory system, RC705-779
Abstract

Abstract Rationale Gap junctions are membrane channels formed by an array of connexins which links adjacent cells realizing an electro- metabolic synapse. Connexin-mediated communication is crucial in the regulation of cell growth, differentiation, and development. The activation and proliferation of phenotypically altered fibroblasts are central events in the pathogenesis of idiopathic pulmonary fibrosis. We sought to evaluate the role of connexin-43, the most abundant gap-junction subunit in the human lung, in the pathogenesis of this condition. Methods We investigated the transcription and protein expression of connexin-43 and the gap-junctional intercellular communication (GJIC) in 5 primary lung fibroblast lines derived from normal subjects (NF) and from 3 histologically proven IPF patients (FF). Results Here we show that connexin-43 mRNA was significantly reduced in FF as demonstrated by standard and quantitative RT-PCR. GJIC was functionally evaluated by means of flow-cytometry. In order to demonstrate that dye spreading was taking place through gap junctions, we used carbenoxolone as a pharmacological gap-junction blocker. Carbenoxolone specifically blocked GJIC in our system in a concentration dependent manner. FF showed a significantly reduced homologous GJIC compared to NF. Similarly, GJIC was significantly impaired in FF when a heterologous NF line was used as dye donor, suggesting a complete defect in GJIC of FF. Conclusion These results suggest a novel alteration in primary lung fibroblasts from IPF patients. The reduced Cx43 expression and the associated alteration in cell-to-cell communication may justify some of the known pathological characteristic of this devastating disease that still represents a challenge to the medical practice.

Published
2006
Full Text
View/download PDF

6. Interaction between human lung fibroblasts and T-lymphocytes prevents activation of CD4+ cells

Author

Crimi Claudia, La Rosa Cristina, Caruso Massimo, Pistorio Maria P, Lo Furno Debora, Gili Elisa, Trovato-Salinaro Elisa, Mastruzzo Claudio, Vancheri Carlo, Failla Marco, and Crimi Nunzio

Subjects
COX-2, ICAM-1, CD3, CD28, LFA, Diseases of the respiratory system, RC705-779
Abstract

Abstract Background T lymphocytes are demonstrated to play an important role in several chronic pulmonary inflammatory diseases. In this study we provide evidence that human lung fibroblasts are capable of mutually interacting with T-lymphocytes leading to functionally significant responses by T-cells and fibroblasts. Methods Human lung fibroblast were co-cultured with PMA-ionomycin activated T-CD4 lymphocytes for 36 hours. Surface as well as intracellular proteins expression, relevant to fibroblasts and lymphocytes activation, were evaluated by means of flow cytometry and RT-PCR. Proliferative responses of T lymphocytes to concanavalin A were evaluated by the MTT assay. Results In lung fibroblasts, activated lymphocytes promote an increase of expression of cyclooxygenase-2 and ICAM-1, expressed as mean fluorescence intensity (MFI), from 5.4 ± 0.9 and 0.7 ± 0.15 to 9.1 ± 1.5 and 38.6 ± 7.8, respectively. Fibroblasts, in turn, induce a significant reduction of transcription and protein expression of CD69, LFA-1 and CD28 in activated lymphocytes and CD3 in resting lymphocytes. In activated T lymphocytes, LFA-1, CD28 and CD69 expression was 16.6 ± 0.7, 18.9 ± 1.9 and 6.6 ± 1.3, respectively, and was significantly reduced by fibroblasts to 9.4 ± 0.7, 9.4 ± 1.4 and 3.5 ± 1.0. CD3 expression in resting lymphocytes was 11.9 ± 1.4 and was significantly reduced by fibroblasts to 6.4 ± 1.1. Intracellular cytokines, TNF-alpha and IL-10, were evaluated in T lymphocytes. Co-incubation with fibroblasts reduced the number of TNF-alpha positive lymphocytes from 54,4% ± 6.12 to 30.8 ± 2.8, while IL-10 positive cells were unaffected. Finally, co-culture with fibroblasts significantly reduced Con A proliferative response of T lymphocytes, measured as MTT absorbance, from 0.24 ± 0.02 nm to 0.16 ± 0.02 nm. Interestingly, while the activation of fibroblasts is mediated by a soluble factor, a cognate interaction ICAM-1 mediated was demonstrated to be responsible for the modulation of LFA-1, CD28 and CD69. Conclusion Findings from this study suggest that fibroblasts play a role in the local regulation of the immune response, being able to modulate effector functions of cells recruited into sites of inflammation.

Published
2005
Full Text
View/download PDF

7. Inhibition or knock out of Inducible nitric oxide synthase result in resistance to bleomycin-induced lung injury

Author

Crimi Nunzio, Gili Elisa, Frasca Giuseppina, Sortino Maria, Mazzon Emanuela, Failla Marco, Di Paola Rosanna, Cuzzocrea Salvatore, Genovese Tiziana, Caputi Achille P, and Vancheri Carlo

Subjects
Diseases of the respiratory system, RC705-779
Abstract

Abstract Background In the present study, by comparing the responses in wild-type mice (WT) and mice lacking (KO) the inducible (or type 2) nitric oxide synthase (iNOS), we investigated the role played by iNOS in the development of on the lung injury caused by bleomycin administration. When compared to bleomycin-treated iNOSWT mice, iNOSKO mice, which had received bleomycin, exhibited a reduced degree of the (i) lost of body weight, (ii) mortality rate, (iii) infiltration of the lung with polymorphonuclear neutrophils (MPO activity), (iv) edema formation, (v) histological evidence of lung injury, (vi) lung collagen deposition and (vii) lung Transforming Growth Factor beta1 (TGF-β1) expression. Methods Mice subjected to intratracheal administration of bleomycin developed a significant lung injury. Immunohistochemical analysis for nitrotyrosine revealed a positive staining in lungs from bleomycin-treated iNOSWT mice. Results The intensity and degree of nitrotyrosine staining was markedly reduced in tissue section from bleomycin-iNOSKO mice. Treatment of iNOSWT mice with of GW274150, a novel, potent and selective inhibitor of iNOS activity (5 mg/kg i.p.) also significantly attenuated all of the above indicators of lung damage and inflammation. Conclusion Taken together, our results clearly demonstrate that iNOS plays an important role in the lung injury induced by bleomycin in the mice.

Published
2005
Full Text
View/download PDF

8. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum

Author

Olmo, Ricardo del, Anderson, Gary, Reddel, Helen, Rabahi, Marcelo, McIvor, Andrew, Sadatsafavi, Mohsen, Weinreich, Ulla, Burgel, Pierre-Régis, Devouassoux, Gilles, Papi, Alberto, Inoue, Hiromasa, Rendon, Adrián, van den Berge, Maarten, Beasley, Richard, García-Navarro, Alvar Agusti, Faner, Rosa, Olaguibel Rivera, José, Janson, Christer, Bilińska-Izydorczyk, Magdalena, Fagerås, Malin, Fihn-Wikander, Titti, Franzén, Stefan, Keen, Christina, Ostridge, Kristoffer, Chalmers, James, Harrison, Timothy, Pavord, Ian, Price, David, Azim, Adnan, Belton, Laura, Blé, Francois-Xavier, Erhard, Clement, Gairy, Kerry, Hughes, Rod, Lassi, Glenda, Müllerová, Hana, Rapsomaniki, Eleni, Scott, Ian Christopher, Chipps, Bradley, Christenson, Stephanie, Make, Barry, Tomaszewski, Erin, Benhabib, Gabriel, Ruiz, Xavier Bocca, Lisanti, Raul Eduardo, Marino, Gustavo, Mattarucco, Walter, Nogueira, Juan, Parody, Maria, Pascale, Pablo, Rodriguez, Pablo, Silva, Damian, Svetliza, Graciela, Victorio, Carlos F., Rolon, Roxana Willigs, Yañez, Anahi, Baines, Stuart, Bowler, Simon, Bremner, Peter, Bull, Sheetal, Carroll, Patrick, Chaalan, Mariam, Farah, Claude, Hammerschlag, Gary, Hancock, Kerry, Harrington, Zinta, Katsoulotos, Gregory, Kim, Joshua, Langton, David, Lee, Donald, Peters, Matthew, Prassad, Lakshman, Sajkov, Dimitar, Santiago, Francis, Simpson, Frederick Graham, Tai, Sze, Thomas, Paul, Wark, Peter, Cançado, José Eduardo Delfini, Cunha, Thúlio, Lima, Marina, Cardoso, Alexandre Pinto, FitzGerald, J. Mark, Anees, Syed, Bertley, John, Bell, Alan, Cheema, Amarjit, Chouinard, Guy, Csanadi, Michael, Dhar, Anil, Dhillon, Ripple, Kanawaty, David, Kelly, Allan, Killorn, William, Landry, Daniel, Luton, Robert, Mandhane, Piushkumar, Pek, Bonavuth, Petrella, Robert, Stollery, Daniel, Wang, Chen, Chen, Meihua, Chen, Yan, Gu, Wei, Christopher Hui, Kim Ming, Li, Manxiang, Li, Shiyue, Lijun, Ma, Qin, Guangyue, Song, Weidong, Tan, Wei, Tang, Yijun, Wang, Tan, Wen, Fuqiang, Wu, Feng, Xiang, PingChao, Xiao, Zuke, Xiong, Shengdao, Yang, Jinghua, Yang, Jingping, Zhang, Caiqing, Zhang, Min, Zhang, Ping, Zhang, Wei, Zheng, Xiaohe, Zhu, Dan, Bueno, Carlos Matiz, Grimaldos, Fabio Bolivar, Arboleda, Alejandra Cañas, de Salazar, Dora Molina, Bendstrup, Elisabeth, Hilberg, Ole, Kjellerup, Carsten, Raherison, Chantal, Bonniaud, Philippe, Brun, Olivier, Chouaid, Christos, Couturaud, Francis, de Blic, Jacques, Debieuvre, Didier, Delsart, Dominique, Demaegdt, Axelle, Demoly, Pascal, Deschildre, Antoine, Egron, Carole, Falchero, Lionel, Goupil, François, Kessler, Romain, Le Roux, Pascal, Mabire, Pascal, Mahay, Guillaume, Martinez, Stéphanie, Melloni, Boris, Moreau, Laurent, Riviere, Emilie, Roux-Claudé, Pauline, Soulier, Michel, Vignal, Guillaume, Yaici, Azzedine, Bals, Robert, Aries, Sven Philip, Beck, Ekkehard, Deimling, Andreas, Feimer, Jan, Grimm-Sachs, Vera, Groth, Gesine, Herth, Felix, Hoheisel, Gerhard, Kanniess, Frank, Lienert, Thomas, Mronga, Silke, Reinhardt, Jörg, Schlenska, Christian, Stolpe, Christoph, Teber, Ishak, Timmermann, Hartmut, Ulrich, Thomas, Velling, Peter, Wehgartner-Winkler, Sabina, Welling, Juergen, Winkelmann, Ernst-Joachim, Barbetta, Carlo, Braido, Fulvio, Cardaci, Vittorio, Clini, Enrico Maria, Costantino, Maria Teresa, Cuttitta, Giuseppina, di Gioacchino, Mario, Fois, Alessandro, Foschino-Barbaro, Maria Pia, Gammeri, Enrico, Inchingolo, Riccardo, Lavorini, Federico, Molino, Antonio, Nucera, Eleonora, Patella, Vincenzo, Pesci, Alberto, Ricciardolo, Fabio, Rogliani, Paola, Sarzani, Riccardo, Vancheri, Carlo, Vincenti, Rigoletta, Endo, Takeo, Fujita, Masaki, Hara, Yu, Horiguchi, Takahiko, Hosoi, Keita, Ide, Yumiko, Inomata, Minehiko, Inoue, Koji, Inoue, Sumito, Kato, Motokazu, Kawasaki, Masayuki, Kawayama, Tomotaka, Kita, Toshiyuki, Kobayashi, Kanako, Koto, Hiroshi, Nishi, Koichi, Saito, Junpei, Shimizu, Yasuo, Shirai, Toshihiro, Sugihara, Naruhiko, Takahashi, Ken-ichi, Tashimo, Hiroyuki, Tomii, Keisuke, Yamada, Takashi, Yanai, Masaru, Rendon, Adrian, Cerino Javier, Ruth, Domínguez Peregrina, Alfredo, Fernández Corzo, Marco, Montano Gonzalez, Efraín, Ramírez-Venegas, Alejandra, Boersma, Willem, Djamin, R.S., Eijsvogel, Michiel, Franssen, Frits, Goosens, Martijn, Graat-Verboom, Lidwien, Veen, Johannes in 't, Janssen, Rob, Kuppens, Kim, van de Ven, Mario, Bakke, Per, Brunstad, Ole Petter, Einvik, Gunnar, Høines, Kristian Jong, Khusrawi, Alamdar, Oien, Torbjorn, Yoon, Ho Joo, Chang, Yoon-Seok, Cho, Young Joo, Hwang, Yong Il, Kim, Woo Jin, Koh, Young-Il, Lee, Byung-Jae, Lee, Kwan-Ho, Lee, Sang-Pyo, Lee, Yong Chul, Lim, Seong Yong, Min, Kyung Hun, Oh, Yeon-Mok, Park, Choon-Sik, Park, Hae-Sim, Park, Heung-Woo, Rhee, Chin Kook, Yoon, Hyoung-Kyu, García-Navarro, Alvar Agustí, Andújar, Rubén, Anoro, Laura, Buendía García, María, Mozo, Paloma Campo, Campos, Sergio, Casas Maldonado, Francisco, Castilla Martínez, Manuel, Cisneros Serrano, Carolina, Comeche Casanova, Lorena, Corbacho, Dolores, Campo Matías, Felix Del, Echave-Sustaeta, Jose, Corral, Gloria Francisco, Gamboa Setién, Pedro, García Clemente, Marta, Núñez, Ignacio García, García Robaina, Jose, García Salmones, Mercedes, Marín Trigo, Jose Maria, Fernandez, Marta Nuñez, Palomo, Sara Nuñez, Pérez de Llano, Luis, Pueyo Bastida, Ana, Rañó, Ana, Rodríguez González-Moro, José, Reig, Albert Roger, Velasco Garrido, José, Curiac, Dan, Lif-Tiberg, Cornelia, Luts, Anders, Råhlen, Lennart, Rustscheff, Stefan, Adams, Frances, Bradman, Drew, Broughton, Emma, Cosgrove, John, Flood-Page, Patrick, Fuller, Elizabeth, Hartley, David, Hattotuwa, Keith, Jones, Gareth, Lewis, Keir, McGarvey, Lorcan, Morice, Alyn, Pandya, Preeti, Patel, Manish, Roy, Kay, Sathyamurthy, Ramamurthy, Thiagarajan, Swaminathan, Turner, Alice, Vestbo, Jørgen, Wedzicha, Wisia, Wilkinson, Tom, Wilson, Pete, Al-Asadi, Lo’Ay, Anholm, James, Averill, Francis, Bansal, Sandeep, Baptist, Alan, Campbell, Colin, Campos, Michael A., Crook, Gretchen, DeLeon, Samuel, Eid, Alain, Epstein, Ellen, Fritz, Stephen, Harris, Hoadley, Hewitt, Mitzie, Holguin, Fernando, Hudes, Golda, Jackson, Richard, Kaufman, Alan, Kaufman, David, Klapholz, Ari, Krishna, Harshavardhan, Lee, Daria, Lin, Robert, Maselli-Caceres, Diego, Mehta, Vinay, Moy, James N., Nwokoro, Ugo, Parikh, Purvi, Parikh, Sudhir, Perrino, Frank, Ruhlmann, James, Sassoon, Catherine, Settipane, Russell A., Sousa, Daniel, Sriram, Peruvemba, Wachs, Richard, Bansal, Aruna T., Agustí, Alvar, Fageras, Malin, Alacqua, Marianna, and Reddel, Helen K.

Published
2023
Full Text
View/download PDF

10. Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study

Author

Benhabib, Gabriel, Ruiz, Xavier Bocca, Olmo, Ricardo del, Lisanti, Raul Eduardo, Marino, Gustavo, Mattarucco, Walter, Nogueira, Juan, Parody, Maria, Pascale, Pablo, Rodriguez, Pablo, Silva, Damian, Svetliza, Graciela, Victorio, Carlos F., Rolon, Roxana Willigs, Yañez, Anahi, Baines, Stuart, Bowler, Simon, Bremner, Peter, Bull, Sheetal, Carroll, Patrick, Chaalan, Mariam, Farah, Claude, Hammerschlag, Gary, Hancock, Kerry, Harrington, Zinta, Katsoulotos, Gregory, Kim, Joshua, Langton, David, Lee, Donald, Peters, Matthew, Prassad, Lakshman, Reddel, Helen, Sajkov, Dimitar, Santiago, Francis, Simpson, Frederick Graham, Tai, Sze, Thomas, Paul, Wark, Peter, Delfini Cançado, José Eduardo, Cunha, Thúlio, Lima, Marina, Cardoso, Alexandre Pinto, Rabahi, Marcelo, Anees, Syed, Bertley, John, Bell, Alan, Cheema, Amarjit, Chouinard, Guy, Csanadi, Michael, Dhar, Anil, Dhillon, Ripple, FitzGerald, J. Mark, Kanawaty, David, Kelly, Allan, Killorn, William, Landry, Daniel, Luton, Robert, Mandhane, Piushkumar, McIvor, Andrew, Pek, Bonavuth, Petrella, Robert, Stollery, Daniel, Chen, Meihua, Chen, Yan, Gu, Wei, Christopher Hui, Kim Ming, Li, Manxiang, Li, Shiyue, Lijun, Ma, Qin, Guangyue, Song, Weidong, Tan, Wei, Tang, Yijun, Wang, Chen, Wang, Tan, Wen, Fuqiang, Wu, Feng, Xiang, PingChao, Xiao, Zuke, Xiong, Shengdao, Yang, Jinghua, Yang, Jingping, Zhang, Caiqing, Zhang, Min, Zhang, Ping, Zhang, Wei, Zheng, Xiaohe, Zhu, Dan, Grimaldos, Fabio Bolivar, Arboleda, Alejandra Cañas, Bueno, Carlos Matiz, Molina de Salazar, Dora, Bendstrup, Elisabeth, Hilberg, Ole, Kjellerup, Carsten, Weinreich, Ulla, Bonniaud, Philippe, Brun, Olivier, Burgel, Pierre-Régis, Chouaid, Christos, Couturaud, Francis, de Blic, Jacques, Debieuvre, Didier, Delsart, Dominique, Demaegdt, Axelle, Demoly, Pascal, Deschildre, Antoine, Devouassoux, Gilles, Egron, Carole, Falchero, Lionel, Goupil, François, Kessler, Romain, Le Roux, Pascal, Mabire, Pascal, Mahay, Guillaume, Martinez, Stéphanie, Melloni, Boris, Moreau, Laurent, Raherison, Chantal, Riviere, Emilie, Roux-Claudé, Pauline, Soulier, Michel, Vignal, Guillaume, Yaici, Azzedine, Aries, Sven Philip, Bals, Robert, Beck, Ekkehard, Deimling, Andreas, Feimer, Jan, Grimm-Sachs, Vera, Groth, Gesine, Herth, Felix, Hoheisel, Gerhard, Kanniess, Frank, Lienert, Thomas, Mronga, Silke, Reinhardt, Jörg, Schlenska, Christian, Stolpe, Christoph, Teber, Ishak, Timmermann, Hartmut, Ulrich, Thomas, Velling, Peter, Wehgartner-Winkler, Sabina, Welling, Juergen, Winkelmann, Ernst-Joachim, Barbetta, Carlo, Braido, Fulvio, Cardaci, Vittorio, Clini, Enrico Maria, Costantino, Maria Teresa, Cuttitta, Giuseppina, di Gioacchino, Mario, Fois, Alessandro, Foschino-Barbaro, Maria Pia, Gammeri, Enrico, Inchingolo, Riccardo, Lavorini, Federico, Molino, Antonio, Nucera, Eleonora, Papi, Alberto, Patella, Vincenzo, Pesci, Alberto, Ricciardolo, Fabio, Rogliani, Paola, Sarzani, Riccardo, Vancheri, Carlo, Vincenti, Rigoletta, Endo, Takeo, Fujita, Masaki, Hara, Yu, Horiguchi, Takahiko, Hosoi, Keita, Ide, Yumiko, Inomata, Minehiko, Inoue, Hiromasa, Inoue, Koji, Inoue, Sumito, Kato, Motokazu, Kawasaki, Masayuki, Kawayama, Tomotaka, Kita, Toshiyuki, Kobayashi, Kanako, Koto, Hiroshi, Nishi, Koichi, Saito, Junpei, Shimizu, Yasuo, Shirai, Toshihiro, Sugihara, Naruhiko, Takahashi, Ken-ichi, Tashimo, Hiroyuki, Tomii, Keisuke, Yamada, Takashi, Yanai, Masaru, Javier, Ruth Cerino, Peregrina, Alfredo Domínguez, Corzo, Marco Fernández, Gonzalez, Efraín Montano, Ramírez-Venegas, Alejandra, Rendon, Adrian, Boersma, Willem, Djamin, R.S., Eijsvogel, Michiel, Franssen, Frits, Goosens, Martijn, Graat-Verboom, Lidwien, Veen, Johannes in 't, Janssen, Rob, Kuppens, Kim, van den Berge, Maarten, van de Ven, Mario, Brunstad, Ole Petter, Einvik, Gunnar, Høines, Kristian Jong, Khusrawi, Alamdar, Oien, Torbjorn, Chang, Yoon-Seok, Cho, Young Joo, Hwang, Yong Il, Kim, Woo Jin, Koh, Young-Il, Lee, Byung-Jae, Lee, Kwan-Ho, Lee, Sang-Pyo, Lee, Yong Chul, Lim, Seong Yong, Min, Kyung Hun, Oh, Yeon-Mok, Park, Choon-Sik, Park, Hae-Sim, Park, Heung-Woo, Rhee, Chin Kook, Yoon, Ho Joo, Yoon, Hyoung-Kyu, García-Navarro, Alvar Agusti, Andújar, Rubén, Anoro, Laura, García, María Buendía, Mozo, Paloma Campo, Campos, Sergio, Maldonado, Francisco Casas, Martínez, Manuel Castilla, Serrano, Carolina Cisneros, Casanova, Lorena Comeche, Corbacho, Dolores, Del Campo Matías, Felix, Echave-Sustaeta, Jose, Corral, Gloria Francisco, Setién, Pedro Gamboa, Clemente, Marta García, Núñez, Ignacio García, Robaina, Jose García, Salmones, Mercedes García, Marín Trigo, Jose Maria, Fernandez, Marta Nuñez, Palomo, Sara Nuñez, Rivera, José Olaguibel, Pérez de Llano, Luis, Bastida, Ana Pueyo, Rañó, Ana, González-Moro, José Rodríguez, Reig, Albert Roger, Garrido, José Velasco, Curiac, Dan, Janson, Christer, Lif-Tiberg, Cornelia, Luts, Anders, Råhlen, Lennart, Rustscheff, Stefan, Adams, Frances, Bradman, Drew, Broughton, Emma, Cosgrove, John, Flood-Page, Patrick, Fuller, Elizabeth, Harrison, Timothy, Hartley, David, Hattotuwa, Keith, Jones, Gareth, Lewis, Keir, McGarvey, Lorcan, Morice, Alyn, Pandya, Preeti, Patel, Manish, Roy, Kay, Sathyamurthy, Ramamurthy, Thiagarajan, Swaminathan, Turner, Alice, Vestbo, Jorgen, Wedzicha, Wisia, Wilkinson, Tom, Wilson, Pete, Al-Asadi, Lo’Ay, Anholm, James, Averill, Frank, Bansal, Sandeep, Baptist, Alan, Campbell, Colin, Campos, Michael A., Chipps, Bradley, Crook, Gretchen, DeLeon, Samuel, Eid, Alain, Epstein, Ellen, Fritz, Stephen, Harris, Hoadley, Hewitt, Mitzie, Holguin, Fernando, Hudes, Golda, Jackson, Richard, Kaufman, Alan, Kaufman, David, Klapholz, Ari, Krishna, Harshavardhan, Lee, Daria, Lin, Robert, Maselli-Caceres, Diego, Mehta, Vinay, Moy, James N., Nwokoro, Ugo, Parikh, Purvi, Parikh, Sudhir, Perrino, Frank, Ruhlmann, James, Sassoon, Catherine, Settipane, Russell A., Sousa, Daniel, Sriram, Peruvemba, Wachs, Richard, Hughes, Rod, Rapsomaniki, Eleni, Keen, Christina, Make, Barry J., Tomaszewski, Erin L., Müllerová, Hana, and Reddel, Helen K.

Published
2022
Full Text
View/download PDF

11. The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study

Author

Benhabib, Gabriel, Mandhane, Piushkumar, Ruiz, Xavier Bocca, McIvor, Andrew, Olmo, Ricardo del, Pek, Bonavuth, Lisanti, Raul Eduardo, Petrella, Robert, Marino, Gustavo, Stollery, Daniel, Mattarucco, Walter, Chen, Meihua, Nogueira, Juan, Chen, Yan, Parody, Maria, Gu, Wei, Pascale, Pablo, Hui, Kim Ming Christopher, Rodriguez, Pablo, Li, Manxiang, Silva, Damian, Li, Shiyue, Svetliza, Graciela, Ma, Lijun, Victorio, Carlos F., Qin, Guangyue, Rolon, Roxana Willigs, Song, Weidong, Yañez, Anahi, Tan, Wei, Baines, Stuart, Tang, Yijun, Bowler, Simon, Wang, Chen, Bremner, Peter, Wang, Tan, Bull, Sheetal, Wen, Fuqiang, Carroll, Patrick, Wu, Feng, Chaalan, Mariam, Xiang, PingChao, Farah, Claude, Xiao, Zuke, Hammerschlag, Gary, Xiong, Shengdao, Hancock, Kerry, Yang, Jinghua, Harrington, Zinta, Yang, Jingping, Katsoulotos, Gregory, Zhang, Caiqing, Kim, Joshua, Zhang, Min, Langton, David, Zhang, Ping, Lee, Donald, Zhang, Wei, Peters, Matthew, Zheng, Xiaohe, Prassad, Lakshman, Zhu, Dan, Reddel, Helen, Bolivar Grimaldos, Fabio, Sajkov, Dimitar, Arboleda, Alejandra Cañas, Santiago, Francis, Bueno, Carlos Matiz, Simpson, Frederick Graham, Molina de Salazar, Dora, Tai, Sze, Bendstrup, Elisabeth, Thomas, Paul, Hilberg, Ole, Wark, Peter, Kjellerup, Carsten, Cançado, José Eduardo Delfini, Weinreich, Ulla, Cunha, Thúlio, Bonniaud, Philippe, Lima, Marina, Brun, Olivier, Cardoso, Alexandre Pinto, Burgel, Pierre-Régis, Rabahi, Marcelo, Chouaid, Christos, Anees, Syed, Couturaud, Francis, Bertley, John, de Blic, Jacques, Bell, Alan, Debieuvre, Didier, Cheema, Amarjit, Delsart, Dominique, Chouinard, Guy, Demaegdt, Axelle, Csanadi, Michael, Demoly, Pascal, Dhar, Anil, Deschildre, Antoine, Dhillon, Ripple, Devouassoux, Gilles, FitzGerald, J. Mark, Egron, Carole, Kanawaty, David, Falchero, Lionel, Kelly, Allan, Goupil, François, Killorn, William, Kessler, Romain, Landry, Daniel, Le Roux, Pascal, Luton, Robert, Mabire, Pascal, Mahay, Guillaume, Ide, Yumiko, Martinez, Stéphanie, Inomata, Minehiko, Melloni, Boris, Inoue, Hiromasa, Moreau, Laurent, Inoue, Koji, Raherison, Chantal, Inoue, Sumito, Riviere, Emilie, Kato, Motokazu, Roux-Claudé, Pauline, Kawasaki, Masayuki, Soulier, Michel, Kawayama, Tomotaka, Vignal, Guillaume, Kita, Toshiyuki, Yaici, Azzedine, Kobayashi, Kanako, Aries, Sven Philip, Koto, Hiroshi, Bals, Robert, Nishi, Koichi, Beck, Ekkehard, Saito, Junpei, Deimling, Andreas, Shimizu, Yasuo, Feimer, Jan, Shirai, Toshihiro, Grimm-Sachs, Vera, Sugihara, Naruhiko, Groth, Gesine, Takahashi, Ken-ichi, Herth, Felix, Tashimo, Hiroyuki, Hoheisel, Gerhard, Tomii, Keisuke, Kanniess, Frank, Yamada, Takashi, Lienert, Thomas, Yanai, Masaru, Mronga, Silke, Javier, Ruth Cerino, Reinhardt, Jörg, Domínguez Peregrina, Alfredo, Schlenska, Christian, Corzo, Marco Fernández, Stolpe, Christoph, Montano Gonzalez, Efraín, Teber, Ishak, Ramírez-Venegas, Alejandra, Timmermann, Hartmut, Rendon, Adrian, Ulrich, Thomas, Boersma, Willem, Velling, Peter, Djamin, R.S., Wehgartner-Winkler, Sabina, Eijsvogel, Michiel, Welling, Juergen, Franssen, Frits, Winkelmann, Ernst-Joachim, Goosens, Martijn, Barbetta, Carlo, Graat-Verboom, Lidwien, Braido, Fulvio, Veen, Johannes in 't, Cardaci, Vittorio, Janssen, Rob, Clini, Enrico Maria, Kuppens, Kim, Costantino, Maria Teresa, van den Berge, Maarten, Cuttitta, Giuseppina, van de Ven, Mario, di Gioacchino, Mario, Brunstad, Ole Petter, Fois, Alessandro, Einvik, Gunnar, Foschino-Barbaro, Maria Pia, Høines, Kristian Jong, Gammeri, Enrico, Khusrawi, Alamdar, Inchingolo, Riccardo, Oien, Torbjorn, Lavorini, Federico, Chang, Yoon-Seok, Molino, Antonio, Cho, Young Joo, Nucera, Eleonora, Hwang, Yong Il, Papi, Alberto, Kim, Woo Jin, Patella, Vincenzo, Koh, Young-Il, Pesci, Alberto, Lee, Byung-Jae, Ricciardolo, Fabio, Lee, Kwan-Ho, Rogliani, Paola, Lee, Sang-Pyo, Sarzani, Riccardo, Lee, Yong Chul, Vancheri, Carlo, Lim, Seong Yong, Vincenti, Rigoletta, Min, Kyung Hun, Endo, Takeo, Oh, Yeon-Mok, Fujita, Masaki, Park, Choon-Sik, Hara, Yu, Park, Hae-Sim, Horiguchi, Takahiko, Park, Heung-Woo, Hosoi, Keita, Rhee, Chin Kook, Yoon, Ho Joo, Morice, Alyn, Yoon, Hyoung-Kyu, Pandya, Preeti, García-Navarro, Alvar Agusti, Patel, Manish, Andújar, Rubén, Roy, Kay, Anoro, Laura, Sathyamurthy, Ramamurthy, García, María Buendía, Thiagarajan, Swaminathan, Mozo, Paloma Campo, Turner, Alice, Campos, Sergio, Vestbo, Jorgen, Maldonado, Francisco Casas, Wedzicha, Wisia, Castilla Martínez, Manuel, Wilkinson, Tom, Serrano, Carolina Cisneros, Wilson, Pete, Comeche Casanova, Lorena, Al-Asadi, Lo’Ay, Corbacho, Dolores, Anholm, James, Campo Matías, Felix Del, Averill, Frank, Echave-Sustaeta, Jose, Bansal, Sandeep, Corral, Gloria Francisco, Baptist, Alan, Gamboa Setién, Pedro, Campbell, Colin, García Clemente, Marta, Campos, Michael A., Núñez, Ignacio García, Chipps, Bradley, Robaina, Jose García, Crook, Gretchen, García Salmones, Mercedes, DeLeon, Samuel, Marín Trigo, Jose Maria, Eid, Alain, Fernandez, Marta Nuñez, Epstein, Ellen, Palomo, Sara Nuñez, Fritz, Stephen, Olaguibel Rivera, José, Harris, Hoadley, de Llano, Luis Pérez, Hewitt, Mitzie, Pueyo Bastida, Ana, Holguin, Fernando, Rañó, Ana, Hudes, Golda, Rodríguez González-Moro, José, Jackson, Richard, Reig, Albert Roger, Kaufman, Alan, Velasco Garrido, José, Kaufman, David, Curiac, Dan, Klapholz, Ari, Janson, Christer, Krishna, Harshavardhan, Lif-Tiberg, Cornelia, Lee, Daria, Luts, Anders, Lin, Robert, Råhlen, Lennart, Maselli-Caceres, Diego, Rustscheff, Stefan, Mehta, Vinay, Adams, Frances, Moy, James N., Bradman, Drew, Nwokoro, Ugo, Broughton, Emma, Parikh, Purvi, Cosgrove, John, Parikh, Sudhir, Flood-Page, Patrick, Perrino, Frank, Fuller, Elizabeth, Ruhlmann, James, Harrison, Timothy, Sassoon, Catherine, Hartley, David, Settipane, Russell A., Hattotuwa, Keith, Sousa, Daniel, Jones, Gareth, Sriram, Peruvemba, Lewis, Keir, Wachs, Richard, McGarvey, Lorcan, Golam, Sarowar Muhammad, Beasley, Richard, FitzGerald, J Mark, Harrison, Tim, Hughes, Rod, Müllerová, Hana, Olaguibel, José María, Rapsomaniki, Eleni, Reddel, Helen K., and Sadatsafavi, Mohsen

Published
2022
Full Text
View/download PDF

12. Adaptive servo‐ventilation for the treatment of intrathecal baclofen‐induced central sleep apnea: A case report.

Author

Schisano, Matteo, Libra, Alessandro, Morana, Giorgio, Vancheri, Carlo, and Spicuzza, Lucia

Subjects
ASPHYXIA neonatorum, FATIGUE (Physiology), SLEEP apnea syndromes, AIR pressure, NEUROLOGICAL disorders
Abstract

Baclofen is a common muscle relaxant agent used in a number of neurological disorders acting at central level and potentially causing adverse respiratory events, still largely unknown at therapeutic doses. We present the case of a young woman with spastic tetraparesis secondary to perinatal asphyxia treated with a standard dose of intrathecal baclofen who developed nocturnal symptoms, somnolence and memory loss during the day. Nocturnal cardio‐respiratory sleep monitoring showed a high number of central sleep apneas (CSA). The patient was adapted and treated with a positive air pressure device, Adaptative Servo‐Ventilator, specific designed to treat CSA particularly in patients with heart failure. The treatment was well tolerated and within few days CSA was reversed. The patient reported a feeling of restful sleep and disappearance of morning tiredness. The efficacy of the treatment was verified with nocturnal cardio‐respiratory monitoring after 2 months and complete resolution of all symptoms was also confirmed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Pulmonary Progressive Fibrosis in Rheumatoid Arthritis and Primary Sjogren Syndrome: Similarities and Differences.

Author

Manfredi, Andreina, Venerito, Vincenzo, Cazzato, Massimiliano, Sambataro, Gianluca, Zanini, Umberto, Gozzi, Filippo, Gentileschi, Stefano, Canofari, Claudia, Atzeni, Fabiola, Cassone, Giulia, Iannone, Florenzo, Laurino, Elenia, Vancheri, Carlo, Luppi, Fabrizio, Cerri, Stefania, and Sebastiani, Marco

Subjects
SJOGREN'S syndrome, IDIOPATHIC pulmonary fibrosis, RHEUMATISM, INTERSTITIAL lung diseases, PULMONARY function tests
Abstract

Background: Progressive pulmonary fibrosis (PPF) has been associated with a worse prognosis, even when interstitial lung disease (ILD) is related to rheumatic diseases. Since many differences are detectable among rheumatic diseases in prevalence and features of ILD, we aimed to investigate features of PPF in different rheumatic diseases, namely rheumatoid arthritis (RA) and primary Sjogren's syndrome (pSS). Methods: In an Italian multicentre cross-sectional study, consecutive pSS or RA patients with a diagnosis of ILD from at least two years were enrolled. For each patient, demographic, clinical, and serological data, other than chest high-resolution computed tomography and lung function tests, were recorded at the enrolment and after 2 years. Results: Among 232 patients, namely 156 RA-ILD and 76 pSS-ILD, a PPF was recorded in 38.8% of cases, without differences between the two diseases. Analysing patients with a PPF, usual interstitial pneumonia was significantly more frequent in RA than pSS (71.4% and 44.4%, respectively; p = 0.019), while ILD preceded the diagnosis of the rheumatic disease in 29.1% of RA and 89.5% of pSS (p < 0.001). Finally, RA patients were significantly younger than pSS at the diagnosis of the rheumatic disease (p < 0.001). Conclusions: In conclusion, although there is a similar prevalence of PPF in RA-ILD and pSS-ILD, we demonstrated for the first time that the two conditions differ in terms of radiological patterns and demographic and clinical features, suggesting that specific factors related to such diseases might influence the lung involvement over time. Prospective studies could investigate if these specificities could induce different responses to the treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Asthma remission one, none and one-hundred thousand: the relevance of the patient's view.

Author

Bonini, Matteo, Barbaglia, Simona, Camiciottoli, Gianna, Del Giacco, Stefano, Di Marco, Fabiano, Matucci, Andrea, Micheletto, Claudio, Papi, Alberto, Pasqualetti, Patrizio, Pelaia, Girolamo, Ricciardolo, Fabio Luigi Massimo, Rogliani, Paola, Senna, Gianenrico, Triggiani, Massimo, Vancheri, Carlo, and Canonica, Giorgio Walter

Subjects
PATIENTS' attitudes, THERAPEUTIC alliance, PATIENT preferences, DISEASE management, INDIVIDUALIZED medicine
Abstract

Objective: Achieving remission in severe asthma holds paramount importance in elevating patient quality of life and reducing both individual and societal burdens associated with this chronic condition. This study centers on identifying pivotal patient-relevant endpoints through standardized, reproducible methods, while also developing a patient-centric definition of remission, essential for effective disease management. Methods: A discrete choice experiment (DCE) was conducted to assess patients' perceptions on the four primary criteria for defining severe asthma remission, as outlined by the SANI survey. Additionally, it investigated the correlation between these perceptions and improvements in the doctor-patient therapeutic alliance during treatment decision-making. Results: 249 patients (70% aged between 31–60, 59% women and 82% without other pathologies requiring corticosteroids) prioritize the use of oral corticosteroids (OCS, 48%) and the Asthma Control Test (ACT, 27%) in defining their condition, ranking these above lung function and exacerbations. This preference for OCS stems from its direct role in treatment, tangible tracking, immediate symptom relief, and being a concrete measure of disease severity compared to the less predictable and quantifiable exacerbations. Conclusions: This study explores severe asthma remission from patients' perspectives using clinician-evaluated parameters. The DCE revealed that most patients highly value OCS and the ACT, prefer moderate improvement, and avoid cortisone cycles. No definitive preference was found for lung function status. Integrating patient-reported information with professional insights is crucial for effective management and future research. Personalized treatment plans focusing on patient preferences, adherence, and alternative therapies aim to achieve remission and enhance quality of life. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Long-Term High-Flow Nasal Therapy in Patients with Bronchiectasis of Different Severity: A Retrospective Cohort Study.

Author

Calabrese, Cecilia, Nolasco, Santi, Annunziata, Anna, Sola, Alessio, Imitazione, Pasquale, Campisi, Raffaele, Simioli, Francesca, Balestrino, Marco, Ferrentino, Laura, Vancheri, Carlo, Crimi, Claudia, and Fiorentino, Giuseppe

Subjects
PULMONARY function tests, BRONCHIECTASIS, SPUTUM, DISEASE exacerbation, DYSPNEA
Abstract

Background/Objectives: High-flow nasal therapy (HFNT) has been shown to reduce exacerbations of COPD and some evidence displays benefits in non-cystic fibrosis bronchiectasis (NCFB) patients. The present study aimed to compare the effectiveness of 12 months of home HFNT on the annual exacerbation rate between mild/moderate and severe NCFB patients, classified by the bronchiectasis severity index (BSI). Secondary outcomes were the evaluation of the dyspnea, pulmonary function, and sputum cultures in both groups. Methods: The study population included NCFB adult patients, with at least one severe exacerbation in the previous year on optimized therapy. NCFB exacerbations, dyspnea (mMRC score), pulmonary function test, and sputum cultures were assessed at baseline and after 12 months of HFNT. Results: A total of 86 NCFB patients were enrolled: 36 in the mild/moderate (BSI < 9) and 50 in the severe (BSI ≥ 9) group. A significant improvement in the annual exacerbation rate was found in both BSI ≥ 9 (p < 0.0001) and BSI < 9 cohorts (p < 0.0001), with a between-group difference of −1 (95% CI: −2 to 0) exacerbations per year (p = 0.0209). The change in the annual exacerbation rate was significantly correlated with BSI (ρ = −0.26, p = 0.0151) and with HFNT daily use (ρ = −0.22, p = 0.0460). The mMRC score significantly improved by −2 points (95% CI: −2 to −1) after treatment in both groups (p < 0.0001). The percentage of patients with P. aeruginosa colonization decreased from 34.9% to 27.9%. Conclusions: Long-term HFNT reduces the annual exacerbation rate in NCFB patients and its effectiveness increases alongside disease severity and daily use of HFNT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)

Author

Bassetti, Matteo, Giacobbe, Daniele Roberto, Bruzzi, Paolo, Barisione, Emanuela, Centanni, Stefano, Castaldo, Nadia, Corcione, Silvia, De Rosa, Francesco Giuseppe, Di Marco, Fabiano, Gori, Andrea, Gramegna, Andrea, Granata, Guido, Gratarola, Angelo, Maraolo, Alberto Enrico, Mikulska, Malgorzata, Lombardi, Andrea, Pea, Federico, Petrosillo, Nicola, Radovanovic, Dejan, Santus, Pierachille, Signori, Alessio, Sozio, Emanuela, Tagliabue, Elena, Tascini, Carlo, Vancheri, Carlo, Vena, Antonio, Viale, Pierluigi, and Blasi, Francesco

Published
2022
Full Text
View/download PDF

23. Eosinophilic Bronchiectasis: Prevalence, Severity, and Associated Features—A Cohort Study.

Author

Campisi, Raffaele, Nolasco, Santi, Mancuso, Manuel, Spinella, Miriam, Vignera, Fabio, Crimi, Nunzio, Vancheri, Carlo, and Crimi, Claudia

Subjects
EOSINOPHILS, NITRIC oxide, DISEASE exacerbation, ETIOLOGY of diseases, LUNGS, BRONCHIECTASIS
Abstract

Background: Bronchiectasis (BE) has been traditionally associated with neutrophilic inflammation, but eosinophilic bronchiectasis (EB) has recently emerged. Data about prevalence, clinical features, and disease severity are lacking. This study aimed to assess the EB prevalence, compare EB with non-EB, evaluate the Type-2 (T2) high endotype in BE (T2-high EB) versus non-T2-high EB, and identify EB predictors. Methods: We conducted a prospective study involving 153 BE patients. The data collected included clinical, radiological, and microbiological findings. BE severity was assessed using the bronchiectasis severity index (BSI), FACED and E-FACED scores, and the bronchiectasis etiology and comorbidity index (BACI). EB was defined as a blood eosinophil count (BEC) ≥ 300 cells/μL, and T2-high EB as BEC ≥ 300 cells/μL with fractional exhaled nitric oxide (FeNO) ≥ 25 ppb. Results: Prevalence was 27% for EB and 20% for T2-high EB. EB patients exhibited poorer lung function and more severe radiologic features, with significantly higher severity scores [BSI, FACED, E-FACED, BACI (p < 0.05)], and a higher median exacerbation rate [4 (2–5) in EB vs. 2 (1–4) in non-EB, p = 0.0002], compared with non-EB patients. T2-high EB patients showed higher severity scores [BSI, FACED, E-FACED (p < 0.05)], as well as worse lung function parameters [FEV1%, FVC%, FEF 25–75% (p < 0.05)] compared with non-T2-high EB patients. In our study, patients with EB exhibited notably worsened lung function and higher BE severity scores compared with their non-EB counterparts, with exacerbations playing a major role in these differences. We found statistically significant positive correlations between BEC and disease severity scores, such as BSI, FACED, and mMRC, as well as an inverse relationship with pulmonary function. The likelihood of EB being present was significantly higher in association with mMRC ≥ 1 (OR = 2.53; 95% CI, 1.26–5.64), exacerbations/year ≥ 1 (OR = 1.27; 95% CI, 1.0–1.63), and chronic PA colonization (OR = 3.9; 95% CI, 1.08–15.8). Conclusions: EB is a distinct endotype. Dyspnea, exacerbations, and PA colonization may be predictive of EB, emphasizing the importance of early detection for improved outcomes. BEC could serve as a useful biomarker of disease severity to consider when diagnosing EB. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Highlights on Future Treatments of IPF: Clues and Pitfalls.

Author

Libra, Alessandro, Sciacca, Enrico, Muscato, Giuseppe, Sambataro, Gianluca, Spicuzza, Lucia, and Vancheri, Carlo

Subjects
IDIOPATHIC pulmonary fibrosis, INTERSTITIAL lung diseases, DRUG target, INDIVIDUALIZED medicine, ARTIFICIAL intelligence, LUNGS
Abstract

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by irreversible scarring of lung tissue, leading to death. Despite recent advancements in understanding its pathophysiology, IPF remains elusive, and therapeutic options are limited and non-curative. This review aims to synthesize the latest research developments, focusing on the molecular mechanisms driving the disease and on the related emerging treatments. Unfortunately, several phase 2 studies showing promising preliminary results did not meet the primary endpoints in the subsequent phase 3, underlying the complexity of the disease and the need for new integrated endpoints. IPF remains a challenging condition with a complex interplay of genetic, epigenetic, and pathophysiological factors. Ongoing research into the molecular keystones of IPF is critical for the development of targeted therapies that could potentially stop the progression of the disease. Future directions include personalized medicine approaches, artificial intelligence integration, growth in genetic insights, and novel drug targets. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Prevalence of Progressive Fibrosing Interstitial Lung Disease in Patients with Primary Sjogren Syndrome.

Author

Manfredi, Andreina, Sambataro, Gianluca, Rai, Alessandra, Cerri, Stefania, Sambataro, Domenico, Vacchi, Caterina, Cassone, Giulia, Vancheri, Carlo, and Sebastiani, Marco

Subjects
SJOGREN'S syndrome, PULMONARY fibrosis, RHEUMATISM, ANTINUCLEAR factors, DISEASE duration
Abstract

Background: Interstitial lung disease (ILD) represents a frequent cause of morbidity and mortality in primary Sjogren syndrome (pSS). However, the prevalence and behavior of pSS-ILD remains incomplete, largely based on retrospective heterogeneous studies. Aim of the study: To investigate the prevalence of progressive pulmonary fibrosis (PPF) in a multicentric cohort of patients with pSS-ILD. Additionally, this study explored possible correlations between PPF and clinical, demographic, and serological features of pSS. Methods: All consecutive patients with pSS-ILD were enrolled in a 6-month period. Clinical, demographic, and serological features of pSS, other than functional and radiological lung features, were collected. Clinical behaviors of ILD other than PPF were also investigated. Results: Seventy-two patients were enrolled. A fibrosing ILD pattern was observed in 65.3% of patients with pSS-ILD; among them, 55.3% showed a PPF. The radiologic pattern (NSIP, UIP, or others) was not associated with PPF; in particular, patients with PFF had UIP in 42.3% of cases and NSIP in 57.7%, without a significant difference with respect to the non-PPF group (p = 0.29). Shorter pSS disease duration, higher age at pSS diagnosis, and lower frequency of antinuclear antibodies were correlated with the PPF subgroup. However, multivariate analysis did not confirm these associations. Discussion: This study provides valuable insights into the prevalence and characteristics of PPF in pSS-ILD. In particular, UIP and NSIP showed a similar evolution towards PPF in patients with pSS; for NSIP, this behavior was more frequent than for other rheumatic diseases. Our results emphasize the importance of early recognition of PPF for timely intervention and careful follow-up. Conclusions: This study provides valuable insights into the prevalence and characteristics of PPF in pSS-ILD. In particular, UIP and NSIP showed a similar evolution towards PPF in patients with pSS; for NSIP, this behavior was more frequent than for other rheumatic diseases. Our results emphasize the importance of early recognition of PPF for timely intervention and careful follow-up. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis

Author

Antoniou, Katerina M., Barber, Christopher M., Behr, Jürgen, Bonella, Francesco, Corte, Tamera, Costabel, Ulrich, Cottin, Vincent, Crestani, Bruno, Dalphin, Jean-Charles, Flaherty, Kevin R., Goh, Nicole, Johannson, Kerri A., Kondoh, Yasuhiro, Lederer, David, Lee, Joyce, Maher, Toby M., Martinez, Fernando J., Morell, Ferran, Noth, Imre, Raghu, Ganesh, Renzoni, Elisabetta, Richeldi, Luca, Ryerson, Christopher J., Ryu, Jay H., Salisbury, Margaret L., Singh, Sheetu, Selman, Moises, Strek, Mary E., Tarlo, Susan M., Tomassetti, Sara, Vancheri, Carlo, Vasakova, Martina, Wolters, Paul, Wells, Athol, Barnes, Hayley, Morisset, Julie, Molyneaux, Philip, Westall, Glen, Glaspole, Ian, and Collard, Harold R.

Published
2020
Full Text
View/download PDF

36. Melatonin Enhances Neural Differentiation of Adipose-Derived Mesenchymal Stem Cells.

Author

Romano, Ivana Roberta, D'Angeli, Floriana, Gili, Elisa, Fruciano, Mary, Lombardo, Giuseppe Angelo Giovanni, Mannino, Giuliana, Vicario, Nunzio, Russo, Cristina, Parenti, Rosalba, Vancheri, Carlo, Giuffrida, Rosario, Pellitteri, Rosalia, and Lo Furno, Debora

Subjects
MESENCHYMAL stem cell differentiation, NEURAL stem cells, MULTIPOTENT stem cells, MESENCHYMAL stem cells, MELATONIN, SCHWANN cells, MESODERM
Abstract

Adipose-derived mesenchymal stem cells (ASCs) are adult multipotent stem cells, able to differentiate toward neural elements other than cells of mesodermal lineage. The aim of this research was to test ASC neural differentiation using melatonin combined with conditioned media (CM) from glial cells. Isolated from the lipoaspirate of healthy donors, ASCs were expanded in a basal growth medium before undergoing neural differentiation procedures. For this purpose, CM obtained from olfactory ensheathing cells and from Schwann cells were used. In some samples, 1 µM of melatonin was added. After 1 and 7 days of culture, cells were studied using immunocytochemistry and flow cytometry to evaluate neural marker expression (Nestin, MAP2, Synapsin I, GFAP) under different conditions. The results confirmed that a successful neural differentiation was achieved by glial CM, whereas the addition of melatonin alone did not induce appreciable changes. When melatonin was combined with CM, ASC neural differentiation was enhanced, as demonstrated by a further improvement of neuronal marker expression, whereas glial differentiation was attenuated. A dynamic modulation was also observed, testing the expression of melatonin receptors. In conclusion, our data suggest that melatonin's neurogenic differentiation ability can be usefully exploited to obtain neuronal-like differentiated ASCs for potential therapeutic strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Rethinking the need for increased clinical and radiological awareness of incidentally discovered interstitial lung abnormalities on CT chest.

Author

Palmucci, Stefano, Reali, Linda, Sambataro, Gianluca, Basile, Antonio, and Vancheri, Carlo

Subjects
INTERSTITIAL lung diseases, COMPUTED tomography, LUNGS, PULMONARY fibrosis, HUMAN abnormalities, IDIOPATHIC pulmonary fibrosis
Abstract

This article discusses the importance of increased clinical and radiological awareness of incidentally discovered interstitial lung abnormalities (ILAs) on CT chest scans. ILAs are radiological abnormalities that are only discovered incidentally and have been associated with a possible evolution to clinical interstitial lung diseases (ILDs). However, ILAs are not a clinical entity themselves and can be challenging to diagnose. The article emphasizes the need for improved reporting and recognition of ILAs by radiologists and clinicians to prevent diagnostic delays and improve patient outcomes. It suggests strategies such as using structured model reports and encouraging the use of artificial intelligence tools to aid in ILA identification. [Extracted from the article]

Published
2024
Full Text
View/download PDF

40. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Author

Albera, Carlo, Antoniou, Katerina M., Altinisik, Goksel, Bendstrup, Elisabeth, Bondue, Benjamin, Borie, Raphael, Brown, Kevin K., Camus, Philippe, Castillo, Diego, Collard, Harold R., Cottin, Vincent, Crimi, Nunzio, Ferrara, Giovanni, Fischer, Aryeh, Gauldie, Jack, Geiser, Thomas, Guenther, Andreas, Hambly, Nathan, Hansell, David M., Harari, Sergio, Jones, Mark G., Keane, Michael, Ley, Brett, Maher, Toby M., Molina-Molina, Maria, Palmucci, Stefano, Poletti, Venerino, Prasse, Antje, Rottoli, Paola, Spagnolo, Paolo, Sterclova, Martina, Torrisi, Sebastiano, Tsitoura, Eliza, Vasakova, Martina, Walsh, Simon L., Wijsenbeek, Marlies S., Wuyts, Wim A., Johannson, Kerri A, Strâmbu, Irina, Ravaglia, Claudia, Grutters, Jan C, Valenzuela, Claudia, Mogulkoc, Nesrin, Luppi, Fabrizio, Richeldi, Luca, Wells, Athol U, Vancheri, Carlo, and Kreuter, Michael

Published
2017
Full Text
View/download PDF

41. Diagnostic delay in bronchiectasis: an Italian perspective.

Author

Chessari, Carlo, Simonetta, Edoardo, Amati, Francesco, Nigro, Mattia, Stainer, Anna, Sotgiu, Giovanni, Puci, Mariangela, Gramegna, Andrea, Blasi, Francesco, Morlacchi, Letizia Corinna, Maria Domenica Buscemi, Agata Alba, Conio, Valentina, Sanci, Vincenzo, Corsico, Angelo G., Faverio, Paola, Michalak, Weronika, Luppi, Fabrizio, Crimi, Claudia, Vancheri, Carlo, and Campisi, Raffaele

Published
2024
Full Text
View/download PDF

42. The Pattern and Progression of "Usual" Interstitial Pneumonia with Autoimmune Features: Comparison with Patients with Classic Interstitial Pneumonia with Autoimmune Features and Idiopathic Pulmonary Fibrosis.

Author

Libra, Alessandro, Colaci, Michele, Spicuzza, Lucia, Luca, Giuliana, Fischetti, Sefora, Pashalidis, Giorgio, Ferrara, Chiara Alfia, Ielo, Giuseppe, Sambataro, Domenico, La Rosa, Giuliana, Libra, Federica, Palmucci, Stefano, Vancheri, Carlo, and Sambataro, Gianluca

Subjects
PULMONARY fibrosis, RHEUMATOID factor, AUTOIMMUNE diseases, MORPHOLOGY, CONNECTIVE tissue diseases, IDIOPATHIC pulmonary fibrosis
Abstract

Background: We proposed the term "UIPAF" to define patients with Usual Interstitial Pneumonia (UIP) associated with only one domain of the classification called "Interstitial Pneumonia with Autoimmune Features" (IPAF). The objective of this study was to evaluate the clinical presentation and prognosis of UIPAF patients, compared with two cohorts, composed of IPAF and idiopathic pulmonary fibrosis (IPF) patients, respectively. Methods: The patients were enrolled as IPAF, UIPAF, or IPF based on clinical, serological, and radiological data and evaluated by a multidisciplinary team. Results: We enrolled 110 patients with IPF, 69 UIPAF, and 123 IPAF subjects. UIPAF patients were similar to IPAF regarding autoimmune features, except for the prevalence of Rheumatoid Factor in UIPAF and anti-SSA in IPAF. A similar proportion of the two cohorts progressed toward a specific autoimmune disease (SAD), with differences in the kind of SAD developed. The real-life management and prognosis of UIPAF patients proved to be almost identical to IPF. Conclusions: UIPAF shared with IPAF similar autoimmune features, suggesting the opportunity to be considered IPAF, excluding the morphological domain by the classification. However, the real-life management and prognosis of UIPAF are similar to IPF. These data suggest a possible modification in the therapeutic management of UIPAF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Assessment of Lung Cancer Development in Idiopathic Pulmonary Fibrosis Patients Using Quantitative High-Resolution Computed Tomography: A Retrospective Analysis

Author

Palmucci, Stefano, Torrisi, Sebastiano E., Falsaperla, Daniele, Stefano, Alessandro, Torcitto, Alfredo G., Russo, Giorgio, Pavone, Mauro, Vancheri, Ada, Mauro, Letizia A., Grassedonio, Emanuele, Sambataro, Gianluca, Puglisi, Silvia, Piciucchi, Sara, Tomassetti, Sara, Poletti, Venerino, Basile, Antonio, and Vancheri, Carlo

Published
2020
Full Text
View/download PDF

48. Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State.

Author

Libra, Alessandro, Ciancio, Nicola, Sambataro, Gianluca, Sciacca, Enrico, Muscato, Giuseppe, Marino, Andrea, Vancheri, Carlo, and Spicuzza, Lucia

Subjects
COVID-19, INFLAMMATION, REMDESIVIR, PNEUMONIA, PARTIAL pressure
Abstract

Remdesivir is one of the most attractive options for patients with hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19). The aim of our study was to evaluate the effect of remdesivir on the hypoxic and inflammatory state in patients with moderate to severe COVID-19. We retrospectively enrolled 112 patients admitted for COVID-19 pneumonia, requiring low-flow oxygen, 57 treated with remdesivir plus standard of care (SoC) and 55 treated only with SoC that were similar for demographic and clinical data. We evaluated changes in hypoxemia and inflammatory markers at admission (Day 0) and after 5 days of treatment (Day 5) and the clinical course of the disease. From Day 0 to Day 5, the ratio of arterial oxygen partial pressure to fractional inspired oxygen (P/F) increased from 222 ± 62 to 274 ± 97 (p < 0.0001) in the remdesivir group and decreased from 223 ± 62 to 183 ± 76 (p < 0.05) in the SoC group. Interleukine-6 levels decreased in the remdesivir (45.9 to 17.5 pg/mL, p < 0.05) but not in the SoC group. Remdesivir reduced the need for ventilatory support and the length of hospitalization. In conclusion, compared to standard care, remdesivir rapidly improves hypoxia and inflammation, causing a better course of the disease in moderate to severe COVID-19. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results